Net Income

With no approved therapies for Hepatitis E, Atea Pharmaceuticals' new drug shows potent preclinical results, offering a potential lifeline for vulnerable patients.

Cell and gene therapy manufacturer OXB posts a dramatic turnaround to profitability, with surging revenues and an ambitious forecast for the coming years.

As Autolus heads to key investor conferences, its strong AUCATZYL® sales and deep pipeline face scrutiny against mounting losses and a curious PR misstep.

Apellis Pharmaceuticals reports its first profitable year on strong SYFOVRE and EMPAVELI sales, but faces pressure to maintain momentum amid competition.

A new report shows patients are rejecting 'overdone' looks for subtle, strategic care, driven by Ozempic, menopause, and a desire for authenticity.

New Phase 1b data for oral drug pociredir reveals a robust boost in fetal hemoglobin, as Fulcrum Therapeutics secures a financial runway into 2029.

Life Time posts record 2025 earnings and a 230% Q4 profit surge, announcing a $500M share buyback and an aggressive expansion of its 'athletic country clubs'.

Planet Fitness reports a 12.1% revenue surge and adds 1.1 million members, proving its model's resilience even as Wall Street weighs future growth.

The junior miner sheds non-core assets to double down on its high-grade Mexican silver project while upgrading to a top-tier U.S. market.

With a record $1.2B order backlog and a bullish 2026 forecast, the specialty vehicle maker also announces a major leadership shift to drive its next growth phase.

With key conferences ahead, Supernus Pharmaceuticals must prove its strategy can deliver growth in the competitive central nervous system drug landscape.

Creatd Inc. executes a 1:20 reverse stock split to chase a national exchange listing. Is it a strategic masterstroke or a sign of deeper struggles?

The department store chain reported strong earnings that surpassed analyst estimates, but declining sales and margin pressure reveal a complex path forward.

The cannabis giant upsizes its credit facility by CAD $15M, signaling strong lender confidence and fueling its ambitious global expansion plans.

The hospitality REIT posts a record year, fueled by strong group bookings at its Gaylord hotels and an aggressive expansion into live entertainment markets.

Beam Therapeutics is set to announce its 2025 financial results and a new liver-targeted therapy, a key moment for its base editing platform and investors.

With promising data in cancer and eczema, all eyes are on Corvus Pharmaceuticals as it presents its lead drug at a major healthcare conference this week.

A former hedge fund manager's stark video presentation warns that AI will permanently alter work and wealth. Are American workers prepared for what's next?

Primoris Services Corp. posted a record $7.6B revenue for 2025, but a Q4 profit dip and project hurdles hint at challenges in its booming renewables arm.

With a new CEO and a key investor conference ahead, Metagenomi bets on its unique metagenomics platform and a hemophilia drug to navigate a tough market.